Patients Stopping Slimming Jabs Gain Back Weight at a Quadrupled Rate Compared to Those on Conventional Diets

Fresh analysis suggests that patients who stop using popular slimming jabs like semaglutide or tirzepatide can put back on lost weight far faster than those who stop conventional diet and exercise regimens.

Published data in a leading medical journal points out that while obese individuals often shed substantial amounts of their body weight while undergoing treatment, the weight returns at an estimated rate of nearly a kilo each month upon discontinuation.

"People buying these medications should be informed of the danger of fast rebound weight gain when the treatment ends," warns researcher Dr. Susan Jebb.

That rate of recovery means a reversion to pre-treatment weight within about a year and a half.

Weighing Approaches

The study, which looked at 37 of studies involving over 9,000 of patients, compared the outcomes of these new drugs with other pills.

Researchers point out that individuals who shed pounds through lifestyle changes alone generally have a less rapid weight regain—approximately 100 grams monthly—once they finish.

Explaining the Quick Regain

Experts suggest the way of the drugs is key to understanding the heightened rebound.

The injections mimic a body's own chemical called GLP-1, which helps regulate appetite.

"Sustained high doses of GLP-1 concentrations several times higher than normal might result in the system to generate a reduced amount of its endogenous GLP-1, and could diminish responsiveness to its actions," noted Dr. Adam Collins, a nutrition researcher.

"Stopping of this medication means hunger is no longer kept in check, making binge eating a significant risk."

An Ongoing Disease?

Health authorities suggest the injections for people with weight-linked health risks, alongside recommended diet and exercise modifications.

Many experts argue that, considering the high risk of relapse, the therapy should be considered long-term.

This view is reinforced by drug manufacturers, who say that the results "highlight the chronic character of excess weight," akin to managing diseases like diabetes.

User Testimonies

Individuals who have stopped the medication describe a intense return of appetite.

"It felt as if something activating and you become starving," recalled an individual.

This challenge is compounded if users have not developed sustainable dietary or behavioural modifications during treatment.

Significant Use

Survey data indicate that a significant number of people in the UK have tried weight-loss jabs in the last 12 months, with demand remaining high.

• Use is more common among women than males.
• The middle-aged age group shows the greatest level of interest.
• Many access the drugs through private prescriptions rather than the NHS.

In conclusion, researchers stress that while the jabs are effective tools for weight loss, they are not a magic cure and long-term success relies on ongoing behavioural management.